Business Segments Pharmaron Beijing Co., Ltd.

Equities

End-of-day quote Shenzhen S.E. Other stock markets 2026-01-16			5-day change	1st Jan Change
31.94 ^CNY	-2.56%		+1.11%	+12.35%

Jan. 14	Pharmaron Beijing to place 58.4 million new H shares at RMB1.00 per share	RE
Jan. 14	Pharmaron Beijing Seeking HK$1.33 Billion via Stock Offering	MT

See more © MarketScreener.com

See more © MarketScreener.com

Breakdown by Business Segment (CNY)

Fiscal Period: December	2020	2021	2022	2023	2024
Medical Laboratory Services
Laboratory Services (Excl. Macromolecule and Cell and Gene Therapy Services)	-	4.57B	6.24B	-	7.05B
Gross Profit	-	1.98B	2.82B	-	3.17B
Laboratory Services	3.26B	-	-	6.66B	-
Gross Profit	1.39B	-	-	2.95B	-
Life Sciences Tools and Services
Chemical and formulation process development and manufacturing services	1.22B	1.75B	2.41B	2.71B	2.99B
Gross Profit	400M	610M	837M	913M	1B
Clinical Research Services	629M	956M	1.39B	1.74B	1.83B
Gross Profit	118M	98.57M	160M	296M	234M
Gene Research and Development
Macromolecule and Cell and Gene Therapy Services	-	151M	195M	425M	408M
Gross Profit	-	-20.89M	-54.11M	-35.27M	-204M
Others	19.55M	24.48M	26.19M	4.61M	6.4M
Gross Profit	10.84M	6.46M	6.83M	1.06M	2.61M
Drug Discovery - Laboratory Chemistry	-	-	-	-	-
Gross Profit	-	-	-	-	-
Drug Discovery - Biology	-	-	-	-	-
Gross Profit	-	-	-	-	-
Drug Development - Drug Safety Evaluation	-	-	-	-	-
Gross Profit	-	-	-	-	-

Geographical breakdown of sales (CNY)

Fiscal Period: December	2020	2021	2022	2023	2024
North America	-	4.78B	6.64B	7.4B	7.85B
Total Assets	-	1.32B	1.81B	2.03B	2.04B
Europe	-	1.16B	1.48B	1.84B	2.27B
Total Assets	-	1.39B	2.15B	2.55B	2.6B
Mainland China	-	1.27B	1.88B	1.97B	1.85B
Asia (Excluding Chinese Mainland)	-	193M	233M	269M	264M
Others	-	33.96M	25.01M	48.87M	39.51M
Total Assets	-	35M	28.6M	21.56M	15.75M
Foreign	4.43B	-	-	-	-
China	700M	-	-	-	-
Total Assets	-	6.68B	9.53B	10.57B	11.24B